C-peptide response and HLA genotypes in subjects with recent-onset type 1 diabetes after immunotherapy with DiaPep277: An exploratory study

Diabetes

Volumn 60, Issue 11, 2011, Pages 3067-3072

  Buzzetti, Raffaella ^a   Cernea, Simona ^b   Petrone, Antonio ^a   Capizzi, Marco ^a   Spoletini, Marialuisa ^a   Zampetti, Simona ^a   Guglielmi, Chiara ^b   Venditti, Chiara ^a   Pozzilli, Paolo ^b,c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; C PEPTIDE; DIAPEP277; HLA ANTIGEN; PLACEBO; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; CHILD; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GENOTYPE; HUMAN; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PANCREAS ISLET BETA CELL; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD;

ADOLESCENT; ADULT; AGE FACTORS; C-PEPTIDE; CHAPERONIN 60; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; FEMALE; GENES, MHC CLASS II; GENETIC ASSOCIATION STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOLOGIC FACTORS; INSULIN-SECRETING CELLS; KINETICS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; YOUNG ADULT;

EID: 80755168854     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db10-0560     Document Type: Article

References (29)

1. Gianani R, Eisenbarth GS. The stages of type 1A diabetes: 2005. Immunol Rev 2005;204:232-249 (Pubitemid 40460505)
2. Leslie RD, Delli Castelli M. Age-dependent influences on the origins of autoimmune diabetes: evidence and implications. Diabetes 2004;53:3033-3040 (Pubitemid 39571713)
3. Bruno G, Cerutti F, Merletti F, et al.; Piedmont Study Group for Diabetes Epidemiology. Residual beta-cell function and male/female ratio are higher in incident young adults than in children: the registry of type 1 diabetes of the province of Turin, Italy, 1984-2000. Diabetes Care 2005;28:312-317 (Pubitemid 40170932)
4. Sabbah E, Savola K, Ebeling T, et al. Genetic, autoimmune, and clinical characteristics of childhood- and adult-onset type 1 diabetes. Diabetes Care 2000;23:1326-1332
5. Valdes AM, Thomson G, Erlich HA, Noble JA. Association between type 1 diabetes age of onset and HLA among sibling pairs. Diabetes 1999;48:1658-1661 (Pubitemid 29356877)
6. Neu A, Ehehalt S, Willasch A, Kehrer M, Hub R, Ranke MB. Varying clinical presentations at onset of type 1 diabetes mellitus in children - epidemiological evidence for different subtypes of the disease? Pediatr Diabetes 2001;2:147-153 (Pubitemid 34071438)
7. Seissler J, de Sonnaville JJ, Morgenthaler NG, et al. Immunological heterogeneity in type I diabetes: presence of distinct autoantibody patterns in patients with acute onset and slowly progressive disease. Diabetologia 1998;41:891-897 (Pubitemid 28365974)
8. Petrone A, Galgani A, Spoletini M, et al. Residual insulin secretion at diagnosis of type 1 diabetes is independently associated with both, age of onset and HLA genotype. Diabetes Metab Res Rev 2005;21:271-275 (Pubitemid 40716159)
9. Knip M, Ilonen J, Mustonen A, Akerblom HK. Evidence of an accelerated B-cell destruction in HLA-Dw3/Dw4 heterozygous children with type 1 (insulin-dependent) diabetes. Diabetologia 1986;29:347-351 (Pubitemid 16060891)
10. Spoletini M, Petrone A, Zampetti S, et al.; IMDIAB Group. Low-risk HLA genotype in Type 1 diabetes is associated with less destruction of pancreatic B-cells 12 months after diagnosis. Diabet Med 2007;24:1487-1490 (Pubitemid 350179444)
11. Raz I, Avron A, Tamir M, et al. Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial. Diabetes Metab Res Rev 2007;23:292-298 (Pubitemid 46851470)
12. Schloot NC, Meierhoff G, Lengyel C, et al. Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials. Diabetes Metab Res Rev 2007;23:276-285 (Pubitemid 46851468)
13. Lazar L, Ofan R, Weintrob N, et al. Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind phase II study. Diabetes Metab Res Rev 2007;23:286-291 (Pubitemid 46851469)
14. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2000;23(Suppl. 1):S4-S19
15. Petrone A, Battelino T, Krzisnik C, et al. Similar incidence of type 1 diabetes in two ethnically different populations (Italy and Slovenia) is sustained by similar HLA susceptible/protective haplotype frequencies. Tissue Antigens 2002;60:244-253 (Pubitemid 35398827)
16. Cerná M. Genetics of autoimmune diabetes mellitus. Wien Med Wochenschr 2008;158:2-12 (Pubitemid 351268496)
17. Maier LM, Wicker LS. Genetic susceptibility to type 1 diabetes. Curr Opin Immunol 2005;17:601-608 (Pubitemid 41506904)
18. Birk OS, Elias D, Weiss AS, et al. NOD mouse diabetes: the ubiquitous mouse hsp60 is a beta-cell target antigen of autoimmune T cells. J Autoimmun 1996;9:159-166 (Pubitemid 26164742)
19. Brudzynski K, Martinez V, Gupta RS. Immunocytochemical localization of heat-shock protein 60-related protein in beta-cell secretory granules and its altered distribution in non-obese diabetic mice. Diabetologia 1992;35:316-324
20. Zanin-Zhorov A, Cahalon L, Tal G, Margalit R, Lider O, Cohen IR. Heat shock protein 60 enhances CD4+ CD25+ regulatory T cell function via innate TLR2 signaling. J Clin Invest 2006;116:2022-2032 (Pubitemid 44033326)
21. Nussbaum G, Zanin-Zhorov A, Quintana F, Lider O, Cohen IR. Peptide p277 of HSP60 signals T cells: inhibition of inflammatory chemotaxis. Int Immunol 2006;18:1413-1419 (Pubitemid 44446819)
22. Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR. β-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 2001;358:1749-1753 (Pubitemid 33152998)
23. Huurman VA, Decochez K, Mathieu C, Cohen IR, Roep BO. Therapy with the hsp60 peptide DiaPep277 in C-peptide positive type 1 diabetes patients. Diabetes Metab Res Rev 2007;23:269-275 (Pubitemid 46851467)
24. Gale EA. The rise of childhood type 1 diabetes in the 20th century. Diabetes 2002;51:3353-3361 (Pubitemid 35403436)
25. Global Burden of Youth Diabetes: Perspectives and Potential. Chapter One: Diabetes in children: epidemiology. Pediatr Diabetes 2007;8(Suppl. 8):10-18
26. Vehik K, Hamman RF, Lezotte D, et al. Trends in high-risk HLA susceptibility genes among Colorado youth with type 1 diabetes. Diabetes Care 2008;31:1392-1396
27. Hermann R, Knip M, Veijola R, et al.; FinnDiane Study Group. Temporal changes in the frequencies of HLA genotypes in patients with Type 1 diabetes - indication of an increased environmental pressure? Diabetologia 2003;46:420-425 (Pubitemid 36547599)
28. Gillespie KM, Bain SC, Barnett AH, et al. The rising incidence of childhood type 1 diabetes and reduced contribution of high-risk HLA haplotypes. Lancet 2004;364:1699-1700 (Pubitemid 39458146)
29. Fourlanos S, Varney MD, Tait BD, et al. The rising incidence of type 1 diabetes is accounted for by cases with lower-risk human leukocyte antigen genotypes. Diabetes Care 2008;31:1546-1549